Hospital Clínic de Barcelona and the Barcelona Public Health Agency coordinate the participation:
Barcelona becomes part of a worldwide research on tuberculosis
Researchers from Barcelona are the only European representatives in this worldwide network
The Tuberculosis Investigation Unit of Barcelona (UITB) receives funding from the U.S. Centers for Disease Control and Prevention (CDC)
This global network will receive more than $90 million over the next 10 years
Barcelona, Tuesday 9 February 2010. The Tuberculosis Trials Consortium (TBTC) strives to conduct research about the diagnosis, medical treatment, and prevention of tuberculosis (TB) infection and disease. The network is composed of a partnership of clinical investigators from the U.S. Centers for Disease Control and Prevention (CDC), public health departments from different countries, as well as medical and pharmaceutical institutions. From now and until 2010, this Consortium will receive more than $90 million to develop more effective tuberculosis treatments. This funding will be distributed among 20 selected research sites, being Barcelona the only European representative: this site will be coordinated by Dr. Joan A. Caylà, from the Barcelona Public Health Agency (ASPB), and Dr. Josep Maria Miró, from Hospital Clínic de Barcelona IDIBAPS. Other participating institutions will be Hospital del Mar, Hospital de Sant Pau, Hospital Universitari MútuaTerrassa, Hospital de Bellvitge and the Tuberculosis Control Unit at Drassanes Primary Care Centre within the framework of the Tuberculosis Investigation Unit of Barcelona (UITB). Over the next 10 years (2010-2020), an international research effort, based on clinical trials with patients, will be carried out. Countries like Brazil, Peru, Spain, South Africa, Uganda, Kenya, Vietnam, the Philippines and China (Hong Kong) will collaborate in this global network though their research sites. The research group at the TBTC will also include 7 sites in the United States. Tuberculosis is a communicable disease caused by Mycobacterium tuberculosis. It usually affects the lungs, but can also affect other parts of the body, such as the brain, kidneys, or spine. According to the World Health Organization estimates, almost one third of the world’s population (2.000 million people) is infected by the disease-causing bacterium. However, the active disease will only develop in certain people, such as those ones with an immune system facing situations such as a transplant, HIV or malnutrition. More than 9 million people around the world become sick with tuberculosis, and almost 2 million die each year.